Table 2.
Parameter | Treatment group |
|||
---|---|---|---|---|
WL group | BG-YOL group | YOL group | BGL group | |
TP (g/L) | 39.54 ± 0.86a,b | 37.59 ± 0.84b | 37.91 ± 1.11b | 40.67 ± 0.84a |
GLU (mmol/L) | 15.82 ± 0.18a | 15.53 ± 0.37a,b | 15.71 ± 0.15a | 14.92 ± 0.20b |
TG (mmol/L) | 13.49 ± 2.10b | 11.76 ± 2.25b | 13.09 ± 2.92b | 20.54 ± 2.01a |
Ca (mmol/L) | 8.27 ± 0.73b | 7.91 ± 0.74b | 10.18 ± 0.87a | 9.64 ± 0.43a,b |
P (mmol/L) | 4.33 ± 0.16a,b | 4.32 ± 0.12a,b | 4.06 ± 0.16b | 4.56 ± 0.12a |
a,bDifferent lowercase letters within a row indicate significant differences (P < 0.05).
Data are presented as means ± SE.
Abbreviations: BG-YOL group, blue–green (435–565 nm) light at phase 1 (1 D–13 wk) followed by yellow–orange (565–630 nm) light at phase 2 (14–20 wk); BGL group, blue–green (435–565 nm) light at phase 1 (1 D–13 wk) and phase 2 (14–20 wk); Ca, calcium; GLU, glucose; P, phosphorus; TG, triglyceride; TP, total protein; WL group, white (400–700 nm) light at phase 1 (1 D–13 wk) and phase 2 (14–20 wk); YOL group, yellow–orange LED (565–630 nm) light at phase 1 (1 D–13 wk) and phase 2 (14–20 wk).